发明名称 |
Method for screening ameliorants of dry skin caused by atopic dermatitis using bleomycin hydrolase activity as indicator |
摘要 |
The present invention provides a method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison with a control drug. |
申请公布号 |
US8906629(B2) |
申请公布日期 |
2014.12.09 |
申请号 |
US201013513537 |
申请日期 |
2010.12.02 |
申请人 |
Shiseido Company, Ltd. |
发明人 |
Hibino Toshihiko;Kamata Yayoi;Yamamoto Mami |
分类号 |
C12Q1/68;C12Q1/34;G01N33/68;C12Q1/37 |
主分类号 |
C12Q1/68 |
代理机构 |
Foley & Lardner LLP |
代理人 |
Foley & Lardner LLP |
主权项 |
1. A method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis in a human subject, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison with a control drug in human cells, wherein expression and/or activity of bleomycin hydrolase is judged to have increased significantly in the case the transcription activity of a gene that encodes bleomycin hydrolase has increased significantly in comparison with that of a control and wherein the transcription activity is judged to have increased significantly in the case binding activity of transcription factors IRF-1, IRF-2, MZF-1, Sp-1 and/or GATA-1 to the transcription regulatory region of a gene that encodes bleomycin hydrolase has increased significantly in comparison with that of a control. |
地址 |
Tokyo JP |